The patent expirations for many biotechnological medicines have prompted the development of copies of biological medicinal products. Unlike generics, biosimilars are similar but not identical to their reference product, because their chemical characteristics are directly related to the manufacturing process which cannot be precisely duplicated. The regulatory policy for biosimilars is complex and in Europe it is regulated mainly by guidelines issued by the European Medicines Agency (EMEA); additional product-class specific guidelines have been developed as in the case of recombinant human erythropoietin (rHuEPO). In 2008, the experience gained with this drug has prompted the development of a new guideline, currently in draft. In this review we critically discuss aspects related to EMEA guidelines, particularly focusing on rHuEPO.

Keywords:
Biosimilars, Epoetin alpha, European Medicines Agency (EMEA) guidelines, Regulatory authorities, Recombinant human erythropoietin
1.
Regulation (EC) No. 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, as amended.
2.
Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to Medicinal Products for Human Use, as amended.
3.
Schellekens H: Biosimilar therapeutics – what do we need to consider? Nephrol Dial Transplant Plus 2009;2(suppl 1):i27–i36.
4.
Guideline on Similar Biological Medicinal Product (CHMP/437/04).
5.
http://www.emea.europa.eu/htms/human/humanguidelines/multidiscipline.htm.
6.
Annex to Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues – Guidance on Similar Medicinal Products Containing Recombinant Erythropoietins (CHMP/ 94526/05), March 2006.
7.
Guideline on similar medicinal products containing recombinant erythropoietins (EMEA/CHMP/BMWP/301636/08), currently in draft.
8.
The Law of Biologic Medicine. Statement of Lester M. Crawford, DVM, PhD, Acting Commissioner of Food and Drugs, Department of Health and Human Services before the Senate Committee on the Judiciary, June 23, 2004 (available at: http://www.fda.gov/NewsEvents/Testimony/ucm113745.htm).
9.
Summary of the FDA’s FY 2010 Budget (available at: http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/BudgetReports/ucm153154.htm).
11.
Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-Derived Products. Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER) April 1996 (available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122879.htm).
12.
Keithi-Reddy SR, Kandasamy S, Singh AK: Pure red cell aplasia due to follow-on epoetin. Kidney Int 2008;74:1617–1622.
13.
Praditpornsilpa K, Tungsanga K, Eiam-Ong S: The Immunogenicity of Biosimilar Recombinant Human Erythropoietin by Subcutaneous Injection for the Treatment of Anemia in Chronic Kidney Disease. Abstract TH-PO130. Renal Week, San Diego/CA, 2009.
14.
Scientific Discussion: Epoetin alpha Hexal EPAR, Procedure No. EMEA/H/C/726, Revision 7, published 13/10/09 (available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/epoetinalfahexal/epoetinalfahexal.htm).
15.
Scientific Discussion, Retacrit EPAR, Procedure No. EMEA/H/C/726, Revision 4, published 06/02/09 (available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/retacrit/retacrit.htm).
16.
Schellekens H: Assessing the bioequivalence of biosimilars. The Retacrit case. Drug Discov Today 2009;14:495–499.
17.
International Nonproprietary Names (INN) for biological and biotechnological substances (a review). World Health Organization, Programme on International Nonproprietary Names (INN), INN Working Document 05.179, 2007 (available at: http://www.who.int/medicines/services/inn/publication/en/index.html).
18.
European Biopharmaceutical Enterprises (EBE), EBE-EFPIA position paper – Naming of biosimilar medicinal products: options for addressing unique safety concerns (2006) (available at: www.ebe-biopharma.org).
19.
European Biopharmaceutical Enterprises (EBE), EBE-EFPIA position paper: Inapplicability of automatic substitution rules to biotechnology products, including biosimilar products (2006) (available at: www.ebe-biopharma.org).
20.
Hughes DA: Biosimilars: Evidential Standards for Health Technology Assessment. Clin Pharmacol Ther 2010;87:257–261.
21.
Locatelli F, Goldsmith D: Biosimilars: uncharted territory. J Nephrol 2007;20:265–267.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.